Sensus Healthcare Fourth Quarter Financial Results Feature Record Revenue and Continued Double-digit Growth Shipped 27 systems during the quarter including 15 SRT-100 Vision systems Conference call begins at 4:30 p.m. Ea

Healthcare Fourth Quarter Financial Results Feature Record Revenue and Continued Double-digit Growth

27 systems during the quarter including 15 SRT-100 Vision systems

call begins at 4:30 p.m. Eastern time today

RATON, Fla. (February 14, 2019) - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the

non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces financial

results for the three and 12 months ended December 31, 2018.

from the fourth quarter of 2018 include (all comparisons are with the fourth quarter of 2017, unless otherwise indicated):

record fourth quarter financial results continue the steady business momentum and double-digit revenue growth we have been reporting

consistently since our initial public offering in 2016," said Joe Sardano, Chairman and Chief Executive Officer. "I

am very pleased with the achievement of our short- and long-term goals to date and we expect to build on this momentum in the

shipped 27 systems during the quarter, and again more than half were our premium SRT-100 Visions, which have enhanced capabilities

such as image guidance, treatment planning software and comprehensive enterprise integration. We are proud to have shipped our

100th Vision system during the quarter. In August 2018 Sensus received FDA 510(k) clearance

to market our new SRT-100+, which added several innovative features to our SRT-100 product for the treatment of non-melanoma skin

cancer and keloids, including an expanded energy range for customized, more precise treatment. We shipped three of these systems

during the quarter, including two to plastic surgeons who installed the unit specifically for the treatment of keloid scars."

Sardano continued, "We were delighted to ship two SRT-100 units to a two-site physician practice in China, thus reflecting

demand for our products despite the current geopolitical uncertainty between the U.S. and China, and China's economic environment.

China has the world's highest incidence of post-surgical keloid scar formation, and we are pleased to be furthering our

efforts to eliminate the suffering of millions of people with this condition in that country.

expect continued interest in our SRT systems for the treatment of keloids on the heels of a peer-reviewed paper published in November

showing a recurrence rate of only 3% among keloidectomy patients treated post-operatively with SRT, compared with a reported recurrence

rate of approximately 71% following keloidectomy without the use of SRT.

Sardano continued, "We continued to spend significantly on R&D in the fourth quarter, however less than the prior year

when we made the initial submission of the 510(k) application for our new Intraoperative Radiation Therapy (IORT) system (Sculptura)

for treating breast and other cancers. Following a months-long process of addressing all FDA questions, we are hopeful the system

will be cleared in the coming weeks. In preparation for the commercial launch, we manufactured several units to be used in key

research institutions and we have completed the expansion of our oncology sales force. We shipped a unit in December to the Perelman

Center for Advanced Medicine at the University of Pennsylvania, and expect this prestigious medical center will provide us with

additional supportive data for the market. We expect our Sculptura system, which features key technological advances and carries

a list price of $1.5 million, will play an important role in the growth of Sensus in the coming years."

Sardano concluded, "In the fourth quarter we had record quarterly revenue of $8.1 million and with control over spending

we were able to achieve net income of $0.1 million and adjusted EBITDA of $0.4 million. The fourth quarter capped an excellent

and active year during which we increased revenues by 28% to $26.4 million, raised almost $16.0 million in net proceeds in an

underwritten offering of common stock, opened a new subsidiary in Israel for R&D and to serve as a sales base for Europe and

the Middle East, and received multiple U.S. and overseas regulatory clearances for our products. We strengthened our management

team with new hires in sales, marketing and clinical development, and engaged additional international distributors. We have an

active plan for 2019 including launching our Sculptura system, increasing awareness for the use of SRT in keloid treatment and

prevention, and signing additional distributors outside the U.S."

Quarter 2018 Financial Results

for the fourth quarter of 2018 increased 25% to $8.1 million, compared with $6.5 million for the fourth quarter of 2017. The increase

was primarily attributable to more units being sold, including an increase in sales of the higher-priced SRT-100 Vision product.

profit for the fourth quarter of 2018 was $4.9 million, or 60.2% of revenues, compared with $4.3 million, or 66.7% of revenues,

for the fourth quarter of 2017. The decrease in gross margin was mainly due to a shift in product mix.

and marketing expense for the fourth quarter of 2018 was $2.4 million, compared with $2.1 million for the fourth quarter of 2017.

The increase was primarily due to higher commission expense directly related to the increase in sales.

and administrative expense for the fourth quarter of 2018 was $1.0 million, compared with $0.9 million for the fourth quarter

and development expense for the fourth quarter of 2018 was $1.5 million, compared with $1.7 million for the fourth quarter of

2017. The decrease was due to higher expenses in the 2017 fourth quarter associated with the initial submission of a 510(k) application

to the FDA for our IORT product.

income for the fourth quarter of 2018 was $0.1 million, or $0.01 per diluted share, compared with a net loss of $(0.4) million,

or $(0.03) per share, for the fourth quarter of 2017.

EBITDA for the fourth quarter of 2018 was $0.4 million, compared with $(0.2) million for the fourth quarter of 2017. Adjusted

EBITDA is defined as earnings before depreciation and amortization, income taxes, interest and stock-compensation expense. Please

see below for a reconciliation between GAAP and non-GAAP financial measures, and the specific reasons these non-GAAP financial

measures are provided.

and investments were $15.4 million as of December 31, 2018, compared with $11.2 million as of December 31, 2017. During the third

quarter of 2018 the Company raised $15.9 million in net proceeds from an underwritten public offering of common stock and repaid

outstanding borrowings on the revolving line of credit.

Year 2018 Financial Results

for 2018 increased 28% to $26.4 million, compared with $20.6 million for 2017. Gross profit for the year was $16.9 million, or

64.0% of revenue, compared with $13.8 million, or 67.0% of revenue, for the prior year.

and marketing expense was $8.5 million for 2018, compared with $8.3 million for 2017. General and administrative expense was $4.1

million for the year, compared with $3.7 million for the prior year. General and administration expense for 2018 included $0.4

million in stock-based compensation expense related to stock grants during the first quarter of 2018. Research and development

expense for 2018 was $6.3 million, compared with $5.5 million for 2017.

net loss for 2018 was $(2.0) million, or $(0.14) per share, compared with a net loss of $(3.7) million, or $(0.28) per share,

EBITDA for 2018 was $(0.4) million, compared with $(2.9) million for 2017.

of Non-GAAP Financial Information

press release contains supplemental financial information determined by methods other than in accordance with accounting principles

generally accepted in the United States (GAAP). Sensus Healthcare management uses Adjusted EBITDA, a non-GAAP financial measure,

in its analysis of performance. Adjusted EBITDA should not be considered a substitute for GAAP basis measures nor should it be

viewed as a substitute for operating results determined in accordance with GAAP. Management believes the presentation of Adjusted

EBITDA, which excludes the impact of interest, income taxes, depreciation, amortization and stock-compensation expense, provides

useful supplemental information that is essential to a proper understanding of the financial results of Sensus Healthcare. Non-GAAP

financial measures are not formally defined by GAAP, and other entities may use calculation methods that differ from those used

by Sensus Healthcare. As a complement to GAAP financial measures, management believes that Adjusted EBITDA assists investors who

follow the practice of some investment analysts who adjust GAAP financial measures to exclude items that may obscure underlying

performance and distort comparability. A reconciliation of the GAAP net loss to Adjusted EBITDA is provided in the schedule below.

SENSUS HEALTHCARE, INC.

Company will host an investment community conference call today beginning at 4:30 p.m. Eastern time, during which management will

discuss financial results for the 2018 fourth quarter, provide a business update and answer questions. To access the conference

call, the dial-in numbers are 855-940-9473 (U.S. Toll Free), 412-317-5220 (International) and 855-669-9657 (Canada Toll Free).

Please direct the operator to be connected to the Sensus Healthcare call.

the conclusion of the conference call, a replay will be available through February 21, 2019 and can be accessed by dialing 877-344-7529

(U.S. Toll Free), 412-317-0088 (International) and 855-669-9658 (Canada Toll Free). All listeners should provide the operator

with the following replay access code: 10127952. An archived webcast of the call will also be available in the Investor Relations

section of the Company's website for a period of time at www.sensushealthcare.com.

Healthcare, Inc. is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma

skin cancers and keloids. Sensus uses a proprietary low-energy X-ray technology known as superficial radiation therapy (SRT),

which is a result of over a decade of dedicated research and development. Sensus has successfully incorporated SRT into its portfolio

of treatment devices, the SRT-100 , SRT-100+ and SRT-100 Vision . To date, SRT technology has been used to

effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. Sensus also offers Sensus

Laser Systems, three next-generation devices that showcase the latest in technology and function for the aesthetic dermatology

more information, visit www.sensushealthcare.com.

press release includes statements that are, or may be deemed, forward-looking statements.'' In some

cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes,"

"estimates," "anticipates," "expects," "plans," "intends," "may,"

"could," "might," "will," "should," "approximately," "potential"